Cortexyme to Present at Investor Conferences in June 2021

Rhea-AI Summary

Cortexyme, Inc. (Nasdaq: CRTX) is advancing a pivotal trial for Alzheimer's disease with top-line data expected in Q4 2021. The COO and CFO, Chris Lowe, will participate in two virtual investor conferences in June 2021: the Jefferies Healthcare Conference on June 2 at 2:00 p.m. EDT and the JMP Securities Life Sciences Conference on June 16 at 3:00 p.m. EDT. Webcasts of these events will be available on Cortexyme's Investor Calendar for 90 days. Cortexyme's innovative therapies target Alzheimer's and other degenerative diseases, focusing on the infectious pathogen P. gingivalis.

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris Lowe, the company’s chief operating officer and chief financial officer, will participate at the following virtual investor conferences in June 2021:

• Jefferies Healthcare Conference on Wednesday, June 2, 2021, at 2:00 p.m. EDT (11:00 a.m. PDT).
• The JMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 3:00 p.m. EDT (12:00 p.m. PDT).

A live webcast of the events will be accessible on the Investor Calendar page under the News & Events heading of Cortexyme’s investor website at ir.cortexyme.com. The webcasts will be archived at that location for 90 days.

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. The company is advancing its disease-modifying pivotal GAIN Trial in mild to moderate Alzheimer's disease with top-line data expected in the fourth quarter of 2021, in addition to growing a proprietary pipeline of first-in-class small molecule therapeutics for Parkinson’s disease, periodontitis, and other diseases with high unmet clinical need. Cortexyme’s lead program targets a specific, infectious pathogen called P. gingivalis found in the brain and other organs and tied to degeneration and inflammation in humans and animal models. The company’s causation evidence for Alzheimer’s disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005260/en/

FAQ

What are the upcoming conferences Cortexyme will participate in?

Cortexyme will participate in the Jefferies Healthcare Conference on June 2, 2021, at 2:00 p.m. EDT and the JMP Securities Life Sciences Conference on June 16, 2021, at 3:00 p.m. EDT.

When is Cortexyme's data expected from the Alzheimer's trial?

Top-line data from Cortexyme's pivotal Alzheimer's trial is expected in the fourth quarter of 2021.

What is the focus of Cortexyme's research?

Cortexyme focuses on developing therapies for Alzheimer's and other degenerative diseases, particularly targeting the infectious pathogen P. gingivalis.

How can I access the webcasts of Cortexyme's investor conferences?

The webcasts can be accessed on Cortexyme's Investor Calendar page and will be archived for 90 days.

What is the stock symbol for Cortexyme?

Cortexyme's stock symbol is CRTX.